Attacking glioblastoma and other solid tumors with CAR-Ts that target multiple antigens

CAR-T therapies that use engineered versions of patients’ own immune cells to recognize cancer antigens have shown great efficacy in certain blood cancers. But they’ve been largely ineffective against solid tumors because of a lack of tumor-specific antigens and the tendency of CAR-Ts to wither in an immunosuppressive tumor microenvironment.

error: Content is protected !!